WNT signaling pathway inhibitors have garnered significant attention for their potential therapeutic applications across various disease contexts. Before delving into their uses, it is essential to understand CD44, a versatile cell surface glycoprotein implicated in multiple cellular processes. CD44 acts as a receptor for hyaluronic acid and other extracellular matrix components, facilitating cell adhesion and migration during tissue development and repair. Furthermore, CD44 interacts with growth factors and cytokines, influencing intracellular signaling pathways that regulate cell survival, proliferation, and differentiation. WNT signaling pathway inhibitors act to block specific components of the WNT pathway, which is critical for embryonic development and adult tissue homeostasis. Dysregulation of this pathway is associated with numerous diseases, and inhibitors are being studied as potential treatments for cancers like colorectal cancer, breast cancer, and hepatocellular carcinoma. Additionally, these inhibitors show promise in the treatment of osteoporosis, a condition affecting millions of people worldwide, as reported by the World Health Organization (WHO). Furthermore, ongoing research explores their potential in neurological disorders, such as Alzheimer's disease, where WNT pathway modulation may offer therapeutic benefits. The versatility of WNT signaling pathway inhibitors highlights their importance as a growing area of research and their potential to address a range of debilitating diseases. Extensive research is being conducted globally to discover new and novel molecules to be used for the treatment of many indications like for Osteoporosis. The development and launch of new products will thus increase the revenue of the market in the forecasted years.
A number of these stimulators are in the market while many are in ongoing clinical trials. 15 companies have many products in their pipelines with 16 products in various stages of clinical trials – 1 in Phase 3, 8 in Phase 2 and 7 in Phase 1 of the clinical trials.
Drugs in the Pipeline of WNT Signalling Pathway Inhibitors
- Lorecivivint (SM04690)
- Foscenvivint (PRI724)
- E7386
- Tegavivint (BC2059)
- SM04755
- Ipafricept (OMP-54F28)
- Vantictumab (OMP-18R5)
- CWP291
- LNG01
- WNT974
- C-82 Topical Gel, 1%
- Cirtuvivint (SM08502)
- Niclosamide (FW-UP)
- Yttrium Y 90 Tabituximab Barzuxetan (OTSA101-DTPA-90Y)
- BI 905677
- XNW7201
Clinical Activity and Developments of WNT Signalling Pathway Inhibitors
As of July 2023, 15 companies have approximately 16 products for 37 diseases. For these diseases, 19 trials are being conducted by players globally. For instance,
- Biosplice Therapeutics Inc is conducting a Phase 3 clinical trial to evaluate the efficacy and safety of a single injection of Lorecivivint 0.07 mg dose in the target knee joint of subjects with Moderate to Severe Osteoarthritis pain of the Knee that is expected to complete by October 2023.
- Biosplice Therapeutics Inc is conducting a Phase 3 clinical trial to evaluate the safety and efficacy of Lorecivivint in subjects with Osteoarthritis of the knee that is expected to complete by September 2024.
- Eisai Inc is conducting a Phase 1b/2 clinical trial of E7386 in combination with Pembrolizumab in previously treated subjects with selected Solid Tumors that is expected to complete by September 2025.
|
Molecule name |
Number of studies |
|
lorecivivint (SM04690) |
13 |
|
foscenvivint (PRI724) |
9 |
|
E7386 |
7 |
|
tegavivint (BC2059) |
6 |
|
SM04755 |
4 |
Target Indication Analysis of WNT Signalling Pathway Inhibitors
WNT signaling pathway inhibitors have emerged as promising candidates for various therapeutic indications, with certain areas showing particular promise. One of the most significant applications lies in cancer treatment. Dysregulation of the WNT pathway is frequently observed in various cancers, including colorectal cancer, breast cancer, and hepatocellular carcinoma. Therefore, inhibitors targeting this pathway hold potential as targeted therapies to inhibit tumor growth and metastasis. Additionally, WNT signaling pathway inhibitors are being investigated for their role in regenerative medicine, particularly in promoting bone healing and tissue repair. Furthermore, these inhibitors are studied for their potential in treating osteoporosis, a condition characterized by reduced bone density and increased fracture risk. Moreover, WNT inhibitors may hold promise in neurological disorders, such as Alzheimer's disease, where the WNT pathway is implicated in synaptic function and neuroprotection. The versatility of WNT signaling pathway inhibitors makes them a promising area of research, offering hope for innovative treatments across multiple debilitating diseases.
WNT Signalling Pathway Inhibitors Market
According to the WHO 2020 report, approximately 2.3 million women were diagnosed with breastt cancer globally and by the end of 2020, 7.8 milion women globally were diagnosed with breast cancer. According to the American Cancer Society’s 2023 report, there is 13% risk for a women in her life to develop breast cancer in the USA. Moreover, according to a report, in 2022 the global prevalence of Osteoporosis in women was 200 million. The prevalence rates of the diseases vary according to the region but a rise has been observed on a global scale. Developed markets like USA and Europe have probable reimbursement policies with respect to the healthcare that acts as a driver for the growth of the market in the future. Therefore, there is a huge opportunity in the gobal as well as segmennted market for the market players.
Latin America
Europe
Asia Pacific
Middle East
North America
Frequently Asked Questions
No WNT signaling pathway Inhibitor has been approved by the FDA.
These are being evaluated for the treatment of many diseases like Alzheimer’s disease, Breast cancer, Colorectal cancer, Osteoporosis and many others.
Biosplice Therapeutics, Samil Pharmaceutical Co. Ltd, Prism Pharmaceuticals, Ohara Pharmaceutical and Eisai Inc are some of the major market players for WNT Signalling Pathway Inhibitors.
Rising incidence of diseases improvement in technologies, development of new treatment lines in the market and rising incidence of various types of diseases like Breast and Colorectal cancer, Alzheimer’s disease and others are the key opportunities for Fibroblast Growth Factor (WNT Signalling Pathway Inhibitors) in the market.
Key Features of the Report
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
- Biosplice Therapeutics
- Samil Pharmaceutical Co. Ltd
- Prism Pharmaceuticals
- Ohara Pharmaceutical
- Eisai Inc
- Iterion Therapeutics
- Biosplice Therapeutics
- Mereo Biopharma
- JW Pharmaceutical
- Biosplice Therapeutics
- Novartis
- First Wave Bio
- OncoTherapy Science Inc
- Boehringer Ingelheim
- Evopoint Biosciences